Amid a raging controversy over
the efficacy of Covaxin, India's first indigenous Covid-19 vaccine
reputed medical journal the lancet Infectious Diseases on Friday said the vaccine produced
tolerable safety outcomes and enhanced immune responses in its Phase 1 trials.